atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
Cigna's Evernorth is investing $100 million through 2028 in specialty pharmacy care.
The AI program called Pharmacy Forward is expected to generate approximately $400 million in value by the end of 2028, according to Evernorth.
Read more here.
Healthcare organizations today face a convergence of pressures that would challenge even the most mature technology enterprises. Artificial intelligence is arriving faster than most health systems can responsibly govern it.
Mergers and acquisitions are accelerating, consolidating institutions with radically different…
Attendees
Sponsors and Exhibitors
Contact us